Prevalence and risk factors associated with resistance-associated mutations to etravirine in a cohort of perinatally HIV-infected children

Etravirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with reduced cross-resistance to first-generation NNRTIs. Because many perinatally HIV-infected patients have been treated with first-generation NNRTIs, they may have acquired resistance-associated mutations to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of antimicrobial chemotherapy 2013-10, Vol.68 (10), p.2344-2348
Hauptverfasser:	Contreras, German A, Bell, Cynthia S, Del Bianco, Gabriela P, Pérez, Norma, Kleinosky, Matthew T, Murphy, James R, Heresi, Gloria P
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-HIV Agents - administration & dosage Anti-HIV Agents - pharmacology Antiretroviral drugs CD4 antigen Child Child, Preschool Childrens health Cohort Studies Drug Resistance, Viral Drug therapy Female HIV HIV - drug effects HIV - genetics HIV - isolation & purification HIV Infections - drug therapy HIV Infections - virology Human immunodeficiency virus Humans Male Mutation Mutation, Missense Patients Prevalence Protease inhibitors Pyridazines - administration & dosage Pyridazines - pharmacology Retrospective Studies Risk Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!